# PROJECT 3: CARDIOVASCULAR HEALTH EFFECTS OF EMERGING HEAT-NOT-BURN TOBACCO PRODUCTS

> **NIH NIH U54** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $326,238

## Abstract

PROJECT SUMMARY/ABSTRACT
Heat-not-burn (HNB) products, which heat a mixture of tobacco and other compounds to temperatures below
those at which combustion occurs, deliver an inhalable aerosol containing nicotine and other chemicals.
Although previous attempts by the tobacco industry to introduce such products have been largely
unsuccessful, Philip Morris International's iQOS is successfully being test marketed in several countries. In
addition, Philip Morris Products S.A. has submitted modified risk tobacco product applications to the FDA to
permit marketing iQOS in the United States. Despite harm reduction claims, the health effects of HNB
products are poorly understood. This project will inform the FDA about this emerging product class before it
reaches widespread use, in contrast to e-cigarettes, which won a substantial market share before the research
community could mobilize to study their effects on health. The proposed studies will evaluate the
cardiovascular effects of HNB products, beginning with iQOS, including effects on cardiac and peripheral
vascular function, and cardiac tissue preservation after acute myocardial infarction, relative to tobacco smoke
and e-cigarette aerosol. These goals will be accomplished with the following specific aims: (1) Understand
chemical properties of HNB aerosol and chemical changes during its generation; (2) Evaluate and understand
cardiovascular health effects of both acute and repeated exposure to HNB aerosol in rats; and (3) Determine if
acute and chronic exposure to HNB aerosol prior to acute myocardial infarction increase the extent of the
resulting cardiac tissue death. The use of validated rat models that reflect human physiology to evaluate
functional and biochemical consequences of exposure will enable evaluation of the potential adverse health
effects of these products. The proposed research addresses the TCORS theme that “understanding combined
health effects, behavior, and impact analysis will provide actionable information for regulation of and public
communications about current and emerging tobacco products” by being relevant not only to the other
biologically-oriented projects (Projects 1 and 2 that study health effects of e-cigarette and/or HNB aerosol), but
also the assessment of cardiovascular risks associated with HNB products will inform the comparison of risk
perceptions in Project 4 with empirically determined harmful effects in this project. The results will also provide
data for the assessments of economic impact of use of these emerging products in Project 5. This integrated
approach will enable the TCORS to provide timely information about this emerging product category that would
have been difficult to obtain otherwise. In particular, by integrating between this project and Project 2,
which is studying cardiovascular effects of iQOS use relative to e-cigarette use in humans, this TCORS
will supply the FDA with information about HNB products as they are entering the market, rat...

## Key facts

- **NIH application ID:** 9999021
- **Project number:** 5U54HL147127-08
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** MATTHEW Lawrence SPRINGER
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $326,238
- **Award type:** 5
- **Project period:** 2013-09-19 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9999021

## Citation

> US National Institutes of Health, RePORTER application 9999021, PROJECT 3: CARDIOVASCULAR HEALTH EFFECTS OF EMERGING HEAT-NOT-BURN TOBACCO PRODUCTS (5U54HL147127-08). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9999021. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
